Differences of characteristics and outcomes between cancer patients and patients with no active cancer hospitalised for a SARS-CoV-2 infection
Patients with solid cancer or haematologic malignancies have been considered to be more susceptible to SARS-CoV-2 infection and to more often develop severe complications. We aimed to compare the differences in clinical features and outcomes of COVID-19 patients with and without cancer. This was a p...
Gespeichert in:
| Veröffentlicht in: | Bulletin du cancer 2021-06, Vol.108, p.581-588 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 588 |
|---|---|
| container_issue | |
| container_start_page | 581 |
| container_title | Bulletin du cancer |
| container_volume | 108 |
| creator | Fenioux, Charlotte Allenbach, Yves Vozy, Aurore Salem, Joe-Élie Maalouf, Georgina Vieira, Matheus Le Joncour, Alexandre Benveniste, Olivier Saadoun, David Frère, Corinne Campedel, Luca Salem, Pierre Gligorov, Joseph Funck-Brentano, Christian Cacoub, Patrice Gougis, Paul |
| description | Patients with solid cancer or haematologic malignancies have been considered to be more susceptible to SARS-CoV-2 infection and to more often develop severe complications. We aimed to compare the differences in clinical features and outcomes of COVID-19 patients with and without cancer.
This was a prospective observational cohort study of consecutive adult patients hospitalised in a COVID-19 unit at Pitié-Salpêtrière Hospital, Paris, France (NCT04320017).
Among the 262 patients hospitalised in a medical ward during the pandemics with a confirmed COVID-19 diagnosis, 62 patients had cancer. Clinical presentation, comorbidities, and outcomes were similar between cancer and non-cancer patients. However, cancer patients were more likely to have been contaminated while being hospitalised.
Oncologic and non-oncologic patients hospitalised for COVID-19 shared similar outcomes in terms of death, admission in intensive care, or thrombosis/bleeding. They should benefit from the same therapeutic strategy as the general population during the COVID-19 pandemic. |
| doi_str_mv | 10.1016/j.bulcan.2021.03.004 |
| format | Article |
| fullrecord | <record><control><sourceid>hal_pubme</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04027578v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>oai_HAL_hal_04027578v1</sourcerecordid><originalsourceid>FETCH-LOGICAL-h245t-416c12cdd8dc9f2bb8e95fbb7e624c8c760fd5bb58ec8a363e2a1335e44c3e223</originalsourceid><addsrcrecordid>eNo9kMtOwzAQRS0EoqXwBwh5yyLBrzjJsiqPIlVCosA2sp2x4iqNq9htxU_wzQSVdjV3Zs69Iw1Ct5SklFD5sEr1tjWqSxlhNCU8JUScoTHNZZnIkubnaEwIyRORZXSErkJYkcEmmLxEI85LKYtCjtHPo7MWeugMBOwtNo3qlYnQuxCdCVh1NfbbaPx62GuIe4AOD1cN9HijooMuHqBTs3exwZ3HQ4rbwZFtfNi4qFoXoMbW91jh5fR9mcz8V8Kw6ywMuO-u0YVVbYCb_zpBn89PH7N5snh7eZ1NF0nDRBYTQaWhzNR1UZvSMq0LKDOrdQ6SCVOYXBJbZ1pnBZhCccmBKcp5BkKYQTM-QfeH3Ea11aZ3a9V_V165aj5dVH8zIgjLs7zY0YG9O7CbrV5DfcKPT-S_bhJ4JA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Differences of characteristics and outcomes between cancer patients and patients with no active cancer hospitalised for a SARS-CoV-2 infection</title><source>Alma/SFX Local Collection</source><creator>Fenioux, Charlotte ; Allenbach, Yves ; Vozy, Aurore ; Salem, Joe-Élie ; Maalouf, Georgina ; Vieira, Matheus ; Le Joncour, Alexandre ; Benveniste, Olivier ; Saadoun, David ; Frère, Corinne ; Campedel, Luca ; Salem, Pierre ; Gligorov, Joseph ; Funck-Brentano, Christian ; Cacoub, Patrice ; Gougis, Paul</creator><creatorcontrib>Fenioux, Charlotte ; Allenbach, Yves ; Vozy, Aurore ; Salem, Joe-Élie ; Maalouf, Georgina ; Vieira, Matheus ; Le Joncour, Alexandre ; Benveniste, Olivier ; Saadoun, David ; Frère, Corinne ; Campedel, Luca ; Salem, Pierre ; Gligorov, Joseph ; Funck-Brentano, Christian ; Cacoub, Patrice ; Gougis, Paul</creatorcontrib><description>Patients with solid cancer or haematologic malignancies have been considered to be more susceptible to SARS-CoV-2 infection and to more often develop severe complications. We aimed to compare the differences in clinical features and outcomes of COVID-19 patients with and without cancer.
This was a prospective observational cohort study of consecutive adult patients hospitalised in a COVID-19 unit at Pitié-Salpêtrière Hospital, Paris, France (NCT04320017).
Among the 262 patients hospitalised in a medical ward during the pandemics with a confirmed COVID-19 diagnosis, 62 patients had cancer. Clinical presentation, comorbidities, and outcomes were similar between cancer and non-cancer patients. However, cancer patients were more likely to have been contaminated while being hospitalised.
Oncologic and non-oncologic patients hospitalised for COVID-19 shared similar outcomes in terms of death, admission in intensive care, or thrombosis/bleeding. They should benefit from the same therapeutic strategy as the general population during the COVID-19 pandemic.</description><identifier>ISSN: 0007-4551</identifier><identifier>EISSN: 1769-6917</identifier><identifier>DOI: 10.1016/j.bulcan.2021.03.004</identifier><identifier>PMID: 33966886</identifier><language>eng ; fre</language><publisher>France: Elsevier</publisher><subject>Immunology ; Life Sciences</subject><ispartof>Bulletin du cancer, 2021-06, Vol.108, p.581-588</ispartof><rights>Copyright © 2021 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-3185-7993 ; 0000-0002-9900-6386 ; 0000-0002-1167-5797</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33966886$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04027578$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Fenioux, Charlotte</creatorcontrib><creatorcontrib>Allenbach, Yves</creatorcontrib><creatorcontrib>Vozy, Aurore</creatorcontrib><creatorcontrib>Salem, Joe-Élie</creatorcontrib><creatorcontrib>Maalouf, Georgina</creatorcontrib><creatorcontrib>Vieira, Matheus</creatorcontrib><creatorcontrib>Le Joncour, Alexandre</creatorcontrib><creatorcontrib>Benveniste, Olivier</creatorcontrib><creatorcontrib>Saadoun, David</creatorcontrib><creatorcontrib>Frère, Corinne</creatorcontrib><creatorcontrib>Campedel, Luca</creatorcontrib><creatorcontrib>Salem, Pierre</creatorcontrib><creatorcontrib>Gligorov, Joseph</creatorcontrib><creatorcontrib>Funck-Brentano, Christian</creatorcontrib><creatorcontrib>Cacoub, Patrice</creatorcontrib><creatorcontrib>Gougis, Paul</creatorcontrib><title>Differences of characteristics and outcomes between cancer patients and patients with no active cancer hospitalised for a SARS-CoV-2 infection</title><title>Bulletin du cancer</title><addtitle>Bull Cancer</addtitle><description>Patients with solid cancer or haematologic malignancies have been considered to be more susceptible to SARS-CoV-2 infection and to more often develop severe complications. We aimed to compare the differences in clinical features and outcomes of COVID-19 patients with and without cancer.
This was a prospective observational cohort study of consecutive adult patients hospitalised in a COVID-19 unit at Pitié-Salpêtrière Hospital, Paris, France (NCT04320017).
Among the 262 patients hospitalised in a medical ward during the pandemics with a confirmed COVID-19 diagnosis, 62 patients had cancer. Clinical presentation, comorbidities, and outcomes were similar between cancer and non-cancer patients. However, cancer patients were more likely to have been contaminated while being hospitalised.
Oncologic and non-oncologic patients hospitalised for COVID-19 shared similar outcomes in terms of death, admission in intensive care, or thrombosis/bleeding. They should benefit from the same therapeutic strategy as the general population during the COVID-19 pandemic.</description><subject>Immunology</subject><subject>Life Sciences</subject><issn>0007-4551</issn><issn>1769-6917</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNo9kMtOwzAQRS0EoqXwBwh5yyLBrzjJsiqPIlVCosA2sp2x4iqNq9htxU_wzQSVdjV3Zs69Iw1Ct5SklFD5sEr1tjWqSxlhNCU8JUScoTHNZZnIkubnaEwIyRORZXSErkJYkcEmmLxEI85LKYtCjtHPo7MWeugMBOwtNo3qlYnQuxCdCVh1NfbbaPx62GuIe4AOD1cN9HijooMuHqBTs3exwZ3HQ4rbwZFtfNi4qFoXoMbW91jh5fR9mcz8V8Kw6ywMuO-u0YVVbYCb_zpBn89PH7N5snh7eZ1NF0nDRBYTQaWhzNR1UZvSMq0LKDOrdQ6SCVOYXBJbZ1pnBZhCccmBKcp5BkKYQTM-QfeH3Ea11aZ3a9V_V165aj5dVH8zIgjLs7zY0YG9O7CbrV5DfcKPT-S_bhJ4JA</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Fenioux, Charlotte</creator><creator>Allenbach, Yves</creator><creator>Vozy, Aurore</creator><creator>Salem, Joe-Élie</creator><creator>Maalouf, Georgina</creator><creator>Vieira, Matheus</creator><creator>Le Joncour, Alexandre</creator><creator>Benveniste, Olivier</creator><creator>Saadoun, David</creator><creator>Frère, Corinne</creator><creator>Campedel, Luca</creator><creator>Salem, Pierre</creator><creator>Gligorov, Joseph</creator><creator>Funck-Brentano, Christian</creator><creator>Cacoub, Patrice</creator><creator>Gougis, Paul</creator><general>Elsevier</general><scope>NPM</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-3185-7993</orcidid><orcidid>https://orcid.org/0000-0002-9900-6386</orcidid><orcidid>https://orcid.org/0000-0002-1167-5797</orcidid></search><sort><creationdate>20210601</creationdate><title>Differences of characteristics and outcomes between cancer patients and patients with no active cancer hospitalised for a SARS-CoV-2 infection</title><author>Fenioux, Charlotte ; Allenbach, Yves ; Vozy, Aurore ; Salem, Joe-Élie ; Maalouf, Georgina ; Vieira, Matheus ; Le Joncour, Alexandre ; Benveniste, Olivier ; Saadoun, David ; Frère, Corinne ; Campedel, Luca ; Salem, Pierre ; Gligorov, Joseph ; Funck-Brentano, Christian ; Cacoub, Patrice ; Gougis, Paul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h245t-416c12cdd8dc9f2bb8e95fbb7e624c8c760fd5bb58ec8a363e2a1335e44c3e223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; fre</language><creationdate>2021</creationdate><topic>Immunology</topic><topic>Life Sciences</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fenioux, Charlotte</creatorcontrib><creatorcontrib>Allenbach, Yves</creatorcontrib><creatorcontrib>Vozy, Aurore</creatorcontrib><creatorcontrib>Salem, Joe-Élie</creatorcontrib><creatorcontrib>Maalouf, Georgina</creatorcontrib><creatorcontrib>Vieira, Matheus</creatorcontrib><creatorcontrib>Le Joncour, Alexandre</creatorcontrib><creatorcontrib>Benveniste, Olivier</creatorcontrib><creatorcontrib>Saadoun, David</creatorcontrib><creatorcontrib>Frère, Corinne</creatorcontrib><creatorcontrib>Campedel, Luca</creatorcontrib><creatorcontrib>Salem, Pierre</creatorcontrib><creatorcontrib>Gligorov, Joseph</creatorcontrib><creatorcontrib>Funck-Brentano, Christian</creatorcontrib><creatorcontrib>Cacoub, Patrice</creatorcontrib><creatorcontrib>Gougis, Paul</creatorcontrib><collection>PubMed</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Bulletin du cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fenioux, Charlotte</au><au>Allenbach, Yves</au><au>Vozy, Aurore</au><au>Salem, Joe-Élie</au><au>Maalouf, Georgina</au><au>Vieira, Matheus</au><au>Le Joncour, Alexandre</au><au>Benveniste, Olivier</au><au>Saadoun, David</au><au>Frère, Corinne</au><au>Campedel, Luca</au><au>Salem, Pierre</au><au>Gligorov, Joseph</au><au>Funck-Brentano, Christian</au><au>Cacoub, Patrice</au><au>Gougis, Paul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differences of characteristics and outcomes between cancer patients and patients with no active cancer hospitalised for a SARS-CoV-2 infection</atitle><jtitle>Bulletin du cancer</jtitle><addtitle>Bull Cancer</addtitle><date>2021-06-01</date><risdate>2021</risdate><volume>108</volume><spage>581</spage><epage>588</epage><pages>581-588</pages><issn>0007-4551</issn><eissn>1769-6917</eissn><abstract>Patients with solid cancer or haematologic malignancies have been considered to be more susceptible to SARS-CoV-2 infection and to more often develop severe complications. We aimed to compare the differences in clinical features and outcomes of COVID-19 patients with and without cancer.
This was a prospective observational cohort study of consecutive adult patients hospitalised in a COVID-19 unit at Pitié-Salpêtrière Hospital, Paris, France (NCT04320017).
Among the 262 patients hospitalised in a medical ward during the pandemics with a confirmed COVID-19 diagnosis, 62 patients had cancer. Clinical presentation, comorbidities, and outcomes were similar between cancer and non-cancer patients. However, cancer patients were more likely to have been contaminated while being hospitalised.
Oncologic and non-oncologic patients hospitalised for COVID-19 shared similar outcomes in terms of death, admission in intensive care, or thrombosis/bleeding. They should benefit from the same therapeutic strategy as the general population during the COVID-19 pandemic.</abstract><cop>France</cop><pub>Elsevier</pub><pmid>33966886</pmid><doi>10.1016/j.bulcan.2021.03.004</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-3185-7993</orcidid><orcidid>https://orcid.org/0000-0002-9900-6386</orcidid><orcidid>https://orcid.org/0000-0002-1167-5797</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-4551 |
| ispartof | Bulletin du cancer, 2021-06, Vol.108, p.581-588 |
| issn | 0007-4551 1769-6917 |
| language | eng ; fre |
| recordid | cdi_hal_primary_oai_HAL_hal_04027578v1 |
| source | Alma/SFX Local Collection |
| subjects | Immunology Life Sciences |
| title | Differences of characteristics and outcomes between cancer patients and patients with no active cancer hospitalised for a SARS-CoV-2 infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T23%3A18%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-hal_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differences%20of%20characteristics%20and%20outcomes%20between%20cancer%20patients%20and%20patients%20with%20no%20active%20cancer%20hospitalised%20for%20a%20SARS-CoV-2%20infection&rft.jtitle=Bulletin%20du%20cancer&rft.au=Fenioux,%20Charlotte&rft.date=2021-06-01&rft.volume=108&rft.spage=581&rft.epage=588&rft.pages=581-588&rft.issn=0007-4551&rft.eissn=1769-6917&rft_id=info:doi/10.1016/j.bulcan.2021.03.004&rft_dat=%3Chal_pubme%3Eoai_HAL_hal_04027578v1%3C/hal_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33966886&rfr_iscdi=true |